Patents by Inventor Michael Allen Flynn

Michael Allen Flynn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-Beta)
    Publication number: 20230134885
    Abstract: The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis comprising administering an antibody that targets a tyrosine phosphatase inhibitor in a subject.
    Type: Application
    Filed: May 27, 2022
    Publication date: May 4, 2023
    Inventors: Kevin PETERS, Michael Allen FLYNN
  • Humanized monoclonal antibodies that target VE-PTP (HPTP-beta)
    Patent number: 11180551
    Abstract: The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis comprising administering an antibody that targets a tyrosine phosphatase inhibitor in a subject.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: November 23, 2021
    Assignee: EyePoint Pharmaceuticals, Inc.
    Inventors: Kevin Peters, Michael Allen Flynn
  • Humanized monoclonal antibodies that target VE-PTP (HPTP-?)
    Patent number: 11136389
    Abstract: The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis comprising administering an antibody that targets a tyrosine phosphatase inhibitor in a subject.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: October 5, 2021
    Assignee: AERPIO PHARMACEUTICALS, INC.
    Inventors: Kevin Peters, Michael Allen Flynn
  • HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-Beta)
    Publication number: 20200270342
    Abstract: The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis comprising administering an antibody that targets a tyrosine phosphatase inhibitor in a subject.
    Type: Application
    Filed: April 17, 2020
    Publication date: August 27, 2020
    Inventors: Kevin PETERS, Michael Allen FLYNN
  • HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-Beta)
    Publication number: 20200239567
    Abstract: The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis comprising administering an antibody that targets a tyrosine phosphatase inhibitor in a subject.
    Type: Application
    Filed: January 29, 2020
    Publication date: July 30, 2020
    Inventors: Kevin Peters, Michael Allen Flynn
  • Humanized monoclonal antibodies that target protein tyrosine phosphatase-beta (HPTP-?/VE-PTP)
    Patent number: 10604569
    Abstract: The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis comprising administering an antibody that targets a tyrosine phosphatase inhibitor in a subject.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: March 31, 2020
    Assignee: AERPIO PHARMACEUTICALS, INC.
    Inventors: Kevin Peters, Michael Allen Flynn
  • Methods of treating ocular conditions by administering humanized monoclonal antibodies that target VE-PTP (HPTP-beta)
    Patent number: 10597452
    Abstract: The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis comprising administering an antibody that targets a tyrosine phosphatase inhibitor in a subject.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: March 24, 2020
    Assignee: AERPIO PHARMACEUTICALS, INC.
    Inventors: Kevin Peters, Michael Allen Flynn
  • Antibodies that target human protein tyrosine phosphatase-beta (HPTP-beta) and methods of use thereof to treat ocular conditions
    Patent number: 10253094
    Abstract: The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis comprising administering an antibody that targets a tyrosine phosphatase inhibitor in a subject.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: April 9, 2019
    Assignee: Aerpio Therapeutics, Inc.
    Inventors: Kevin Peters, Michael Allen Flynn
  • HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-Beta)
    Publication number: 20190077863
    Abstract: The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis comprising administering an antibody that targets a tyrosine phosphatase inhibitor in a subject.
    Type: Application
    Filed: November 5, 2018
    Publication date: March 14, 2019
    Inventors: Kevin Peters, Michael Allen Flynn
  • HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-Beta)
    Publication number: 20190077862
    Abstract: The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis comprising administering an antibody that targets a tyrosine phosphatase inhibitor in a subject.
    Type: Application
    Filed: November 5, 2018
    Publication date: March 14, 2019
    Inventors: Kevin Peters, Michael Allen Flynn
  • HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-Beta)
    Publication number: 20180022804
    Abstract: The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis comprising administering an antibody that targets a tyrosine phosphatase inhibitor in a subject.
    Type: Application
    Filed: July 19, 2017
    Publication date: January 25, 2018
    Inventors: Kevin Peters, Michael Allen Flynn